Arvinas, Pfizer Announce $2.4B Licensing Agreement For Protein-Degrader Based Breast Cancer Therapy


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


  • Arvinas Inc (NASDAQ:ARVN) and Pfizer Inc (NYSE:PFEhave collaborated to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. 
  • The estrogen receptor is a well-known disease driver in most breast cancers. 
  • ARV-471 is currently in a Phase 2 dose expansion trial for estrogen receptor ER+/HER2- locally advanced or metastatic breast cancer. 
  • Under the terms of the agreement, Pfizer will pay Arvinas $650 million upfront and make a $350 million equity investment, equivalent to a 7% stake in Arvinas.
  • The companies will equally share worldwide development costs, commercialization expenses, and profits.
  • Arvinas is also eligible to receive up to $400 million in approval milestones and up to $1 billion in commercial milestones, in addition to sharing profits on ARV-471 worldwide.
  • The Companies will initiate two additional trials of ARV-471 in 2021, including a second Phase 1b combination trial with everolimus and a trial in the neoadjuvant setting. 
  • In 2022, Arvinas and Pfizer expect to initiate Phase 3 studies across lines of therapy in metastatic breast cancer, including combinations with Ibrance, followed by pivotal studies in the early breast cancer setting. 
  • Price Action: ARVN shares are up 7.09% at $83.05, while PFE shares are down 0.05% at $41.02 during the premarket session on the last check Thursday.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsHealth CareContractsMoversTrading IdeasGeneralbreast cancerBriefs